Sumitomo Pharma Co., Ltd. (FRA:DPM)

Sumitomo Pharma Statistics

Total Valuation

Sumitomo Pharma has a market cap or net worth of EUR 4.98 billion. The enterprise value is 6.08 billion.

Market Cap	4.98B
Enterprise Value	6.08B

Important Dates

The last earnings date was Friday, January 30, 2026.

Earnings Date	Jan 30, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	397.29M
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	0.04%
Owned by Institutions (%)	14.26%
Float	183.27M

Valuation Ratios

The trailing PE ratio is 8.32.

PE Ratio	8.32
Forward PE	n/a
PS Ratio	2.02
PB Ratio	3.17
P/TBV Ratio	n/a
P/FCF Ratio	19.46
P/OCF Ratio	17.20
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.55, with an EV/FCF ratio of 23.75.

EV / Earnings	10.16
EV / Sales	2.46
EV / EBITDA	8.55
EV / EBIT	10.25
EV / FCF	23.75

Financial Position

The company has a current ratio of 1.40, with a Debt / Equity ratio of 0.90.

Current Ratio	1.40
Quick Ratio	0.91
Debt / Equity	0.90
Debt / EBITDA	1.99
Debt / FCF	5.50
Interest Coverage	3.59

Financial Efficiency

Return on equity (ROE) is 48.39% and return on invested capital (ROIC) is 22.11%.

Return on Equity (ROE)	48.39%
Return on Assets (ROA)	8.12%
Return on Invested Capital (ROIC)	22.11%
Return on Capital Employed (ROCE)	17.95%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	642,725
Profits Per Employee	156,064
Employee Count	3,832
Asset Turnover	0.54
Inventory Turnover	1.95

Taxes

Income Tax	-81.31M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +251.43% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+251.43%
50-Day Moving Average	13.44
200-Day Moving Average	8.98
Relative Strength Index (RSI)	43.55
Average Volume (20 Days)	570

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sumitomo Pharma had revenue of EUR 2.46 billion and earned 598.04 million in profits. Earnings per share was 1.51.

Revenue	2.46B
Gross Profit	1.46B
Operating Income	588.83M
Pretax Income	516.73M
Net Income	598.04M
EBITDA	706.19M
EBIT	588.83M
Earnings Per Share (EPS)	1.51

Balance Sheet

The company has 311.39 million in cash and 1.41 billion in debt, with a net cash position of -1.10 billion.

Cash & Cash Equivalents	311.39M
Total Debt	1.41B
Net Cash	-1.10B
Net Cash Per Share	n/a
Equity (Book Value)	1.57B
Book Value Per Share	3.95
Working Capital	457.05M

Cash Flow

In the last 12 months, operating cash flow was 289.41 million and capital expenditures -33.60 million, giving a free cash flow of 255.81 million.

Operating Cash Flow	289.41M
Capital Expenditures	-33.60M
Free Cash Flow	255.81M
FCF Per Share	n/a

Margins

Gross margin is 59.24%, with operating and profit margins of 23.91% and 24.28%.

Gross Margin	59.24%
Operating Margin	23.91%
Pretax Margin	20.98%
Profit Margin	24.28%
EBITDA Margin	28.67%
EBIT Margin	23.91%
FCF Margin	10.39%

Dividends & Yields

Sumitomo Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	0.00%
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	12.02%
FCF Yield	5.14%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sumitomo Pharma has an Altman Z-Score of 1.96 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.96
Piotroski F-Score	5